Alterations of the HBP1 transcriptional repressor are associated with invasive breast cancer.

Invasive breast cancer has a high risk of recurrence to incurable disease and needs improved prognostic and therapeutic tools. Our work combines clinical and molecular analyses to show that the transcriptional repressor HBP1 may be a new target for invasive breast cancer. Previous work indicated that HBP1 regulated proliferation and senescence and inhibited Wnt signaling. Two of these functions have been associated with invasive breast cancer. In 76 breast tumors, we identified 10 HBP1 mutations/variants that were associated with fully invasive breast cancer. In a separate analysis, we found that a subset of invasive breast cancer specimens also had reduced HBP1 mRNA levels. These clinical correlations suggested that mutation or reduction of HBP1 occurs in invasive breast cancer and that HBP1 might regulate the proliferation and invasiveness of this breast cancer type. Analysis of the HBP1 mutants showed they were functionally defective for suppressing Wnt signaling. To test the consequences of reduced HBP1 levels, we used RNA interference to knock down HBP1 and observed increased Wnt signaling, tumorigenic proliferation, and invasiveness in cell and animal breast cancer models. Lastly, statistical analysis of a breast cancer patient database linked reduced HBP1 expression to breast cancer recurrence. In considering two-gene criteria for relapse potential, reduced expression of HBP1 and SFRP1, which is another Wnt inhibitor that was recently linked to invasive breast cancer, strikingly correlated with recurrence. Together, these data indicate that HBP1 may be a molecularly and clinically relevant regulator of breast cancer transitions that eventually lead to poor prognosis.

[1]  Wei Dong Chen,et al.  Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer , 2004, Nature Genetics.

[2]  S. Aaronson,et al.  An autocrine mechanism for constitutive Wnt pathway activation in human cancer cells. , 2004, Cancer cell.

[3]  Bob Y. Liu,et al.  The transforming activity of Wnt effectors correlates with their ability to induce the accumulation of mammary progenitor cells , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[4]  C. D. HAAGENSEN,et al.  Diseases of the Breast , 1972 .

[5]  K. Subbaramaiah,et al.  PEA3 Is Up-regulated in Response to Wnt1 and Activates the Expression of Cyclooxygenase-2* , 2001, The Journal of Biological Chemistry.

[6]  R. Champlin,et al.  Nonmyeloablative stem cell transplantation for lymphoma. , 2004, Seminars in oncology.

[7]  S. Smerdon,et al.  Human HMG box transcription factor HBP1: a role in hCD2 LCR function , 1999, The EMBO journal.

[8]  H. Clevers,et al.  Wnt signalling in stem cells and cancer , 2005, Nature.

[9]  T. Hla,et al.  Overexpression of Cyclooxygenase-2 Is Sufficient to Induce Tumorigenesis in Transgenic Mice* , 2001, The Journal of Biological Chemistry.

[10]  Max S Wicha,et al.  Cancer stem cells: an old idea--a paradigm shift. , 2006, Cancer research.

[11]  Ludwine Messiaen,et al.  Differentiating pathogenic mutations from polymorphic alterations in the splice sites of BRCA1 and BRCA2 , 2003, Genes, chromosomes & cancer.

[12]  K. Eric Paulson,et al.  HBP1 Repression of the p47phox Gene: Cell Cycle Regulation via the NADPH Oxidase , 2004, Molecular and Cellular Biology.

[13]  Cynthia A Afshari,et al.  Histologically normal human mammary epithelia with silenced p16(INK4a) overexpress COX-2, promoting a premalignant program. , 2004, Cancer cell.

[14]  Hui Zhang,et al.  Involvement of Retinoblastoma Protein and HBP1 in Histone H10 Gene Expression , 2000, Molecular and Cellular Biology.

[15]  M. McDevitt,et al.  The HBP1 Transcriptional Repressor Participates in RAS-Induced Premature Senescence , 2006, Molecular and Cellular Biology.

[16]  J. Foekens,et al.  Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer , 2005, The Lancet.

[17]  Pang-Kuo Lo,et al.  Epigenetic suppression of secreted frizzled related protein 1 (SFRP1) expression in human breast cancer , 2006, Cancer biology & therapy.

[18]  Tony Kouzarides,et al.  The HMG-box transcription factor HBP1 is targeted by the pocket proteins and E1A , 1997, Oncogene.

[19]  Robert D Cardiff,et al.  The transcriptional repressor Snail promotes mammary tumor recurrence. , 2005, Cancer cell.

[20]  A. Yee,et al.  The Transcriptional Repressor HBP1 Is a Target of the p38 Mitogen-Activated Protein Kinase Pathway in Cell Cycle Regulation , 2003, Molecular and Cellular Biology.

[21]  E T BELL,et al.  The Diseases of the Breast , 1925, Nature.

[22]  P. Goss,et al.  The role of COX-2 inhibition in breast cancer treatment and prevention. , 2004, Seminars in oncology.

[23]  H. Shih,et al.  Regulation of Differentiation by HBP1, a Target of the Retinoblastoma Protein , 1998, Molecular and Cellular Biology.

[24]  R. Eisenman,et al.  HBP1 and Mad1 repressors bind the Sin3 corepressor PAH2 domain with opposite helical orientations , 2004, Nature Structural &Molecular Biology.

[25]  G. Kristiansen,et al.  Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis , 2006, Oncogene.

[26]  W. Hahn,et al.  Roots and stems: stem cells in cancer , 2006, Nature Medicine.

[27]  Sung-Chul Lim.  Role of COX-2, VEGF and cyclin D1 in mammary infiltrating duct carcinoma. , 2003, Oncology reports.

[28]  Bradley P. Coe,et al.  A tiling resolution DNA microarray with complete coverage of the human genome , 2004, Nature Genetics.

[29]  P. Polakis.  Wnt signaling and cancer. , 2000, Genes & development.

[30]  Chris Albanese,et al.  Negative regulation of the Wnt–β‐catenin pathway by the transcriptional repressor HBP1 , 2001, The EMBO journal.

[31]  Louise R Howe,et al.  Wnt Signaling and Breast Cancer , 2004, Cancer biology & therapy.

[32]  Thomas D. Wu,et al.  Repressor roles for TCF-4 and Sfrp1 in Wnt signaling in breast cancer , 2006, Oncogene.

[33]  M. Hung,et al.  β-Catenin, a novel prognostic marker for breast cancer: Its roles in cyclin D1 expression and cancer progression , 2000 .

[34]  J. Price,et al.  Studies of human breast cancer metastasis using nude mice , 1990, Cancer and Metastasis Reviews.

[35]  M. McDevitt,et al.  The HBP1 transcriptional repressor and the p38 MAP kinase: unlikely partners in G1 regulation and tumor suppression. , 2004, Gene.

[36]  H. Varmus,et al.  Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[37]  D. Hanahan,et al.  Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. , 2004, Cancer cell.

[38]  M. Goldrick.  RNase cleavage‐based methods for mutation/SNP detection, past and present , 2001, Human mutation.

[39]  C. Brisken,et al.  Increased Wnt signaling triggers oncogenic conversion of human breast epithelial cells by a Notch-dependent mechanism. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[40]  C Jodice,et al.  The AXH module: an independently folded domain common to ataxin‐1 and HBP1 , 2003, FEBS letters.

[41]  D. Wazer,et al.  Suppression of Wnt Signaling by the Green Tea Compound (–)-Epigallocatechin 3-Gallate (EGCG) in Invasive Breast Cancer Cells , 2006, Journal of Biological Chemistry.

[42]  A. Leiter,et al.  HMG Box Transcriptional Repressor HBP1 Maintains a Proliferation Barrier in Differentiated Liver Tissue , 2001, Molecular and Cellular Biology.

[43]  T. Barrette,et al.  ONCOMINE: a cancer microarray database and integrated data-mining platform. , 2004, Neoplasia.

[44]  H. Shih,et al.  HBP1: a HMG box transcriptional repressor that is targeted by the retinoblastoma family. , 1997, Genes & development.